CA
KROS icon

CHI Advisors’s Keros Therapeutics KROS Stock Holding History

CHI Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$13M Buy
407,633
+5,515
+1% +$206K 5.15% 7
2023
Q2 		$16.2M Buy
402,118
+141,059
+54% +$6.18M 4.9% 6
2023
Q1 		$11.1M Buy
261,059
+46,000
+21% +$2.32M 2.96% 7
2022
Q4 		$10.3M Buy
215,059
+14,830
+7% +$693K 2.75% 9
2022
Q3 		$7.53M Buy
200,229
+96,800
+94% +$3.36M 2.03% 10
2022
Q2 		$2.86M Buy
103,429
+41,200
+66% +$1.81M 1.09% 20
2022
Q1 		$3.38M Buy
62,229
+44,711
+255% +$2.3M 1.44% 18
2021
Q4 		$1.02M Buy
17,518
+4,891
+39% +$244K 0.34% 19
2021
Q3 		$500K Sell
12,627
-103,779
-89% -$3.69M 0.15% 19
2021
Q2 		$4.94M Sell
116,406
-284,062
-71% -$15.4M 1.15% 14
2021
Q1 		$24.6M Sell
400,468
-33,384
-8% -$2.12M 4.93% 7
2020
Q4 		$30.6M Sell
433,852
-135,606
-24% -$8.55M 8.62% 5
2020
Q3 		$22M Sell
569,458
-10,286
-2% -$408K 7.81% 5
2020
Q2 		$21.7M Buy
+579,744
New +$17.9M 8.49% 4

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

CHI Advisors's KROS Position: Q3 2023 in Review

CHI Advisors increased its Keros Therapeutics (KROS) stake by 1.4% in Q3 2023, buying an estimated $206K and bringing the position to 407,633 shares worth $13M. The position accounts for 5.15% of the portfolio, ranked #7.

CHI Advisors first reported a position in KROS in Q2 2020 and has held it in 14 quarters since. The position peaked at $30.6M in Q4 2020. 107 funds tracked by Wall St. Rank hold KROS as of Q3 2023.

  • CHI Advisors held 407,633 shares of Keros Therapeutics worth $13M as of Q3 2023.
  • CHI Advisors bought 5,515 Keros Therapeutics shares in Q3 2023, an estimated $206K.
  • Keros Therapeutics made up 5.15% of CHI Advisors's portfolio in Q3 2023, its #7 holding.
  • CHI Advisors first reported a position in Keros Therapeutics in Q2 2020 and has held it in 14 quarters since.
  • CHI Advisors's Keros Therapeutics position peaked at $30.6M in Q4 2020.
  • 107 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2023.

Based on CHI Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.